Toggle light / dark theme

Generation of an ARHGAP11B-transgenic mouse line.

To generate a stable transgenic mouse line that expresses an ARHGAP11B protein, we first determined the temporal and spatial expression patterns of human ARHGAP11A and human ARHGAP11B mRNAs by qPCR of foetal human neocortical tissue at various developmental stages (gestational weeks 12–21; Fig EV1A and B) and by analysing previously published RNA-seq data sets of defined isolated NPC and neuron populations (Florio et al, 2015) (Fig EV1C and D), respectively. As the expression patterns of ARHGAP11A and ARHGAP11B mRNAs were found to be similar, we decided to generate the transgenic mouse line by converting one allele of the mouse Arhgap11a gene into a mutant mouse ARHGAP11B gene (mARHGAP11B), using the CRISPR/Cas9 genome editing technology (for details, see Materials and Methods). In m ARHGAP11B, the 55 nucleotides of Arhgap11a that in humans would be deleted from the ARHGAP11B mRNA by splicing using the new splice-donor site are replaced by the 141 nucleotides encoding the human-specific 47-amino acid sequence plus three nucleotides to generate a translational stop codon (Fig EV1E). Unless indicated otherwise, the ARHGAP11B-transgenic mice obtained (referred to as 11B mice hereafter) were used as heterozygous animals, that is, with one mouse Arhgap11a allele being replaced by m ARHGAP11B. The resulting ARHGAP11B protein will be expressed in developing mouse neocortex under the control of the native mouse Arhgap11a promotor.

Critical advances in the investigation of brain functions and treatment of brain disorders are hindered by our inability to selectively target neurons in a noninvasive manner in the deep brain.

This study aimed to develop sonothermogenetics for noninvasive, deep-penetrating, and cell-type-specific neuromodulation by combining a thermosensitive ion channel TRPV1 with focused ultrasound (FUS)-induced brief, non-noxious thermal effect.

The sensitivity of TRPV1 to FUS sonication was evaluated in vitro. It was followed by in vivo assessment of sonothermogenetics in the activation of genetically defined neurons in the mouse brain by two-photon calcium imaging. Behavioral response evoked by sonothermogenetic stimulation at a deep brain target was recorded in freely moving mice. Immunohistochemistry staining of ex vivo brain slices was performed to evaluate the safety of FUS sonication.

The idea is simple: decades of research have found certain genes that seem to increase the chance of Alzheimer’s and other dementias. The numbers range over hundreds. Figuring out how each connects or influences another—if at all—takes years of research in individual labs. What if scientists unite, tap into a shared resource, and collectively solve the case of why Alzheimer’s occurs in the first place?

The initiative’s secret weapon is induced pluripotent stem cells, or iPSCs. Similar to most stem cells, they have the ability to transform into anything—a cellular genie, if you will. iPSCs are reborn from regular adult cells, such as skin cells. When transformed into a brain cell, however, they carry the original genes of their donor, meaning that they harbor the original person’s genetic legacy—for example, his or her chance of developing Alzheimer’s in the first place. What if we introduce Alzheimer’s-related genes into these reborn stem cells, and watch how they behave?

By studying these iPSCs, we might be able to follow clues that lead to the genetic causes of Alzheimer’s and other dementias—paving the road for gene therapies to nip them in the bud.

Doctors are reporting improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumor cells. Few such drugs are approved now, but the approach may become a new way to treat patients with other hard-to-reach or inoperable cancers.

Biobots could help us with new organs! 😃


Computer scientists and biologists have teamed up to create a creature heretofore unseen on Earth: a living robot. Made from the cells of frogs and designed by artificial intelligence, they’re called xenobots, and they may soon revolutionize everything from how we fight pollution to organ transplants.

#Xenobots #Moonshot #BloombergQuicktake.
——-
Like this video? Subscribe: http://www.youtube.com/Bloomberg?sub_confirmation=1
Become a Quicktake Member for exclusive perks: http://www.youtube.com/bloomberg/join.

QuickTake Originals is Bloomberg’s official premium video channel. We bring you insights and analysis from business, science, and technology experts who are shaping our future. We’re home to Hello World, Giant Leap, Storylines, and the series powering CityLab, Bloomberg Businessweek, Bloomberg Green, and much more.

Subscribe for business news, but not as you’ve known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.

Visit our partner channel QuickTake News for breaking global news and insight in an instant.

All cells on Earth are made of phospholipid membranes. Now astronomers have found the component molecules in interstellar space.


One potential explanation is that the Earth was seeded from space with the building blocks for life. The idea is that space is filled with clouds of gas and dust that contain all the organic molecules necessary for life.

Indeed, astronomers have observed these buildings blocks in interstellar gas clouds. They can see amino acids, the precursors of proteins and the machinery of life. They can also see the precursors of ribonucleotides, molecules that can store information in the form of DNA.

But there is another crucial component for life – molecules that can form membranes capable of encapsulating and protecting the molecules of life in compartments called protocells. On Earth, the membranes of all cells are made of molecules called phospholipids. But these have never been observed in space. Until now.

Many of the fundamental features of life don’t necessarily have to be the way they are. Chance plays a major role in evolution, and there are always alternate paths that were never explored, simply because whatever evolved previously happened to be good enough. One instance of this idea is the genetic code, which converts the information carried by our DNA into the specific sequence of amino acids that form proteins. There are scores of potential amino acids, many of which can form spontaneously, but most life uses a genetic code that relies on just 20 of them.

Over the past couple of decades, scientists have shown that it doesn’t have to be that way. If you supply bacteria with the right enzyme and an alternative amino acid, they can use it. But bacteria won’t use the enzyme and amino acid very efficiently, as all the existing genetic code slots are already in use.

In a new work, researchers have managed to edit bacteria’s genetic code to free up a few new slots. They then filled those slots with unnatural amino acids, allowing the bacteria to produce proteins that would never be found in nature. One side effect of the reprogramming? No viruses could replicate in the modified bacteria.

Radiation therapy was first used to treat cancer more than 100 years ago. About half of all cancer patients still receive it at some point during their treatment. And until recently, most radiation therapy was given much as it was 100 years ago, by delivering beams of radiation from outside the body to kill tumors inside the body.

Though effective, external radiation can also cause collateral damage. Even with modern radiation therapy equipment, “you have to [hit] normal tissue to get to a tumor,” said Charles Kunos, M.D., Ph.D., of NCI’s Cancer Therapy Evaluation Program (CTEP). The resulting side effects of radiation therapy depend on the area of the body treated but can include loss of taste, skin changes, hair loss, diarrhea, and sexual problems.

Now, researchers are developing a new class of drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells. The last several years have seen an explosion of research and clinical trials testing new

Scientists created a synthetic genome for a bacterium by stringing together building blocks of DNA — and the new genome made the microbe immune to viral infection.

Even when exposed to a cocktail of bacteriophages — viruses that infect bacteria — the designer Escherichia coli remained unscathed, while an unmodified version of the bacterium quickly succumbed to the viral attack and died, the research team reported in their new study, published Thursday (June 3) in the journal Science. That’s because viruses usually hijack a cell’s internal machinery to make new copies of themselves, but in the designer E. coli, that machinery no longer existed.

This is a technological triumph.


Twenty-one years ago, researchers announced the first “draft” of sequencing the complete human genome. It was a monumental achievement, but the sequence was still missing about 8 percent of the genome. Now, scientists working together around the world say they’ve finally filled in that reclusive 8 percent.

If their work holds up to peer review and it turns out they really did sequence and assemble the human genome in its entirety, gaps and all, it could change the future of medicine.